Feedback / Questions
HER2Bi-armed ATC - TransTarget, Barbara Ann Karmanos Cancer Institute
Keytruda (pembrolizumab) - Merck (MSD)
https://aacrjournals.org/clincancerres/article-abstract/doi/10.1158/1078-0432.CCR-22-1601/709809/Phase-II-trial-of-Pembrolizumab-and-Anti-CD3-x?redirectedFrom=fulltext
Oct 18, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next